Nova Biomedical was formed from the merger of Advanced Instruments (acquired in 2020) and Nova Biomedical (acquired in 2025) - two businesses that have each been dedicated to increasing productivity and ensuring quality in the biopharmaceutical, clinical and food & beverage markets for many decades.
Nova Biomedical designs and commercializes innovative, differentiated analytical instrumentation products that help their global customer base improve product quality and safety, meet regulatory requirements, improve patient care, and reduce costs. The company's products are used in over 100 countries by leading biopharmaceutical companies, hospitals, and food & beverage products.
Nova Biomedical has multiple organic and non-organic opportunities for long-term profitable growth due to its innovative, differentiated product portfolio, strong and durable underlying growth rates in each of the company's core markets, and numerous attractive add-on acquisition opportunities.
|
Patricia Industries ownership (capital/votes): 99/99 |